The present findings suggest that CXCR2 is responsible for neutrophil chemotaxis and margination induced by IL-8. This selective antagonist will be a useful tool compound to define the role of CXCR2 in inflammatory diseases where neutrophils play a major role.
The recruitment of inflammatory cells into sites of tissue damage is a normal physiological response designed to fight infection, remove damaged cells, and stimulate healing. However, the excessive recruitment of such cells often exacerbates tissue damage, slows healing, and in some cases leads to host death. Therefore, inhibition of inflammatory cell recruitment may be an appropriate therapeutic strategy in a number of inflammatory diseases, such as reperfusion injury, arthritis, asthma, and inflammatory bowel disease.
The recruitment of neutrophils from post-capillary venules depends initially upon rolling of neutrophils via the interaction of neutrophil expressed sLex with endothelial expressed Eselectin, followed by attachment through the up-regulation of CD11b/CD18 (Mac-1), and diapedesis via a haptotactic gradient of IL-8 1 (1) . The up-regulation of CD11b/CD18 on neutrophils appears to be mediated via IL-8 binding to neutrophil cell surface receptors (2) .
IL-8 is a member of the super family of proinflammatory proteins known as chemokines, which are approximately 8 kDa in size. In human neutrophils, IL-8 binds with similar affinity to two distinct 7-TMRs, CXCR1 (3) and CXCR2 (4), whereas closely related chemokines containing a common amino-terminal Glu 4 -Leu 5 -Arg 6 (ELR) amino acid sequence, including GRO␣, GRO␤, GRO␥, NAP-2, and ENA-78, bind only to CXCR2 (5) . Both CXCR1 and CXCR2 are present on the surface of human neutrophils and a subset of T-cells (3, 4, 6, 7) . Recent reports indicate that transendothelial migration of CLA ϩ Tcells is dependent on CXCR2 (8) . In human neutrophils it is unclear whether chemotaxis is mediated by one or both receptors. In vitro studies using anti-receptor monoclonal antibodies, and cell lines stably expressing CXCR1 and CXCR2, have led to conflicting reports as to the importance of the two receptors in human neutrophil IL-8-induced chemotaxis (9 -11) .
Evidence in support of a role for ELR containing CXC chemokines in the pathogenesis of inflammation has resulted from studies manipulating the chemokine system in animal models. Neutralization of IL-8 with a monoclonal antibody in rabbits resulted in the suppression of a delayed type hypersensitivity reaction, which correlated with inhibition of both lymphocyte and neutrophil infiltration in the skin lesions (12) . Additional studies with a monoclonal antibody demonstrated potent inhibition of neutrophil recruitment in a rabbit model of endotoxininduced pleurisy (13) and in rabbit lung reperfusion injury (14) . In mice, both injection of a monoclonal antibody to MIP-2, the mouse homologue of GRO, or targeted disruption of the IL-8 receptor resulted in decreased neutrophil-mediated inflammatory responses (14 -17) .
In this paper, the identification of the first potent and selective non-peptide antagonist of a chemokine receptor is described. Using this small molecule antagonist it appears that inhibition of CXCR2 is sufficient to prevent IL-8-induced neutrophil chemotaxis in vitro and sequestration in vivo. SB 225002 should be a useful tool compound to define the pathophysiological role of CXCR2.
EXPERIMENTAL PROCEDURES
Cloning of CXCR1 and CXCR2-The two IL-8 receptors were cloned by reverse transcription polymerase chain reaction. Total RNA from human neutrophils was prepared using a GuSCN/CsCl gradient and cDNA synthesis was primed with oligo(dT). Sequence specific primers (CXCR1 (5Ј-3Ј), CTAGAATTCCCTGGCCGGTGCTTCAGTTAGACTAA-ACC, GGTAGCTACTTCCTTATAGAGAGATCTCCTTCG; CXCR2 (5Ј-3Ј), GATGAATTCGTCAGGATTTAAGTTTACCTCAAAAATGG, GGA-GGACGGATTCACGTCGGGAGATCTTAC) were used to amplify CXCR1 and CXCR2 cDNAs. Receptor sequences were identical to those published (3, 4) , except for a conservative Thr to Ser change at residue 276 of CXCR1. These receptors were cloned into a mammalian expression vector containing a cytomegalovirus promoter and dihydrofolate reductase selection. Chinese hamster ovary (CHO) cell lines expressing either CXCR1 (CHO-CXCR1) or CXCR2 (CHO-CXCR2) were generated by single cell cloning following electroporation of the expression vector and selection by growth in nucleoside-free medium followed by amplification in 80 nM methotrexate. High expressing clones were identified using 125 I-IL-8 binding to cells. Radioligand Binding Experiments-CHO-CXCR1 and CHO-CXCR2 membranes were prepared according to Kraft and Anderson (18) . Assays were performed in 96-well microtiter plates where the reaction mixture contained 1.0 g/ml membrane protein in 20 mM Bis-Trispropane, pH 8.0, with 1.2 mM MgSO 4 , 0.1 mM EDTA, 25 mM NaCl, and 0.03% CHAPS and SB 225002 (10 mM stock in Me 2 SO) added at the indicated concentrations, the final Me 2 SO concentration was Ͻ1% under standard binding conditions. Binding was initiated by addition of 0.25 nM 125 I-IL-8 (Amersham Pharmacia Biotech, 2,200 Ci/mmol). After 1-h incubation at room temperature the plate was harvested using a Tomtec 96-well harvester onto a glass fiber filtermat blocked with 1% polyethyleneimine, 0.5% BSA and washed three times with 25 mM NaCl, 10 mM Tris⅐HCl, 1 mM MgSO 4 , 0.5 mM EDTA, 0.03% CHAPS, pH 7.4. The filter was dried, sealed in a sample bag containing 10 ml of Wallac 205 Betaplate liquid scintillation fluid, and counted with a Wallac 1205 Betaplate liquid scintillation counter. Other binding assays were performed according to previously published reports: C5a (19) , fMLP (20) , LTB 4 (21), and LTD 4 (22) . Inhibition of Ca 2ϩ Mobilization-Human neutrophils were separated from whole blood of healthy volunteers by the one-step Hypaque-Ficoll method (24) . HL60 cells were differentiated, under incubation conditions, with Me 2 SO (0.5%) for 3 days. Cells (PMN, HL60, CXCR1-RBL-2H3, or 3ASubE) were loaded with Fura-2AM as described previously (25) . For antagonist studies, SB 225002 (final Me 2 SO Ͻ 0.35%) was added at the indicated concentrations, to 10 6 cells/ml in Krebs-RingerHenseleit buffer, followed 15 s later by agonist at the designated concentration. The maximal calcium concentration attained after agonist stimulation was quantitated as described previously (25) .
Inhibition of Neutrophil Chemotaxis-Neutrophils were washed twice with phosphate-buffered saline (PBS) and resuspended in PBS containing 1 mM MgCl 2 and 1 mM CaCl 2 . Cell motility was determined using a modified Boyden chamber procedure as described (26) . For measurement of chemotaxis, lower chambers were filled with 30 l of IL-8 (1 nM) or GRO␣ (10 nM), the empty upper chambers were lowered into place, and 50 l of a PMN suspension (5 ϫ 10 6 cells/ml), without (control) or with SB 225002, was added at the indicated concentrations. SB 225002, dissolved in Me 2 SO (100%) at 10 mg/ml, was diluted in PBS to the desired concentration; the final Me 2 SO concentration was Ͻ0.1%. Neutrophil migration proceeded for 60 min at 37°C in the cell incubator, after which the chamber was disassembled. Following fixation (75% methanol) and staining (Diff-Quick) migrated cells were counted in four successive high power fields (HPF).
Inhibition of Neutrophil Sequestration in Vivo-The in vivo neutrophil sequestration model was performed in rabbits as reported previously (27) . Using sterile techniques, rabbits were surgically fitted with an implanted cannula in the external jugular vein. IL-8 (150 ng/kg/min) or fMLP (5 ng/kg/min) was directly infused into the blood in the absence or presence of SB 225002 (1.39 -5.5 g/kg/min) via the marginal ear vein. Blood samples were withdrawn at 2.5-5-min intervals via the vascular access port in the external jugular. White blood cell counts were determined with a Coulter counter, and differential counts were done using blood smears stained with Diff-Quick. Percent change of PMN count was determined relative to the base-line value.
RESULTS AND DISCUSSION
To determine the feasibility of targeting individual IL-8 receptors with non-peptide, low molecular weight antagonists, a high throughput screen was configured using 125 I-IL-8 binding to membranes of CHO-CXCR1 or CHO-CXCR2 cells. One compound identified from this screen was SK&F 83589 (Fig. 1A) , which selectively inhibited 125 I-IL-8 binding to CHO-CXCR2 with an IC 50 of 500 nM. Chemical modification of SK&F 83589 led to SB 225002, N-(2-hydroxy-4-nitrophenyl)-NЈ-(2-bromophenyl)urea (Fig. 1B) , which inhibited 125 I-IL-8 binding to CHO-CXCR2 membranes with an IC 50 ϭ 22 nM (Fig. 2) . SB 225002, at concentrations up to 3.3 M (Fig. 2) To determine if SB 225002 was a functional CXCR2 antagonist, we monitored its effects on intracellular calcium mobilization stimulated by IL-8 or GRO␣. Cross-desensitization studies with Me 2 SO differentiated HL60 cells indicated that these cells predominantly express CXCR2 (ϳ80%) with a smaller number of CXCR1 (ϳ20%) receptors (Fig. 3A) . In these cells, SB 225002 produced a concentration-dependent inhibition of both IL-8-and GRO␣-mediated calcium mobilization with IC 50 values of 8 and 10 nM, respectively (Fig. 3B) . Similarly, in 3ASubE (28) cells stably transfected with CXCR2, SB 225002 dose-dependently inhibited calcium mobilization induced by both GRO␣ and IL-8, with IC 50 values of 20 and 40 nM, respectively (Fig. 3B) . In contrast to HL60 cells, human neutrophils express equal numbers of CXCR1 and CXCR2 on their cell surface. In these cells, SB 225002 inhibited GRO␣-, but not IL-8-, stimulated calcium mobilization (IC 50 values ϭ 30 nM and Ͼ10 M, respectively, Fig. 3C ). In addition, in RBL-2H3 cells, stably transfected with CXCR1, SB 225002 failed to inhibit calcium 
FIG. 1. Structures of SK&F 83589 (A) and the high affinity analog SB 225002 (B).

FIG. 2.
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mobilization induced by either IL-8 or LTD 4 (IC 50 Ͼ 10 M, Fig.  3C ). The failure of SB 225002 to block IL-8-induced calcium mobilization in human neutrophils, presumably reflects the ability of IL-8 to circumvent the blockade of CXCR2 by activating CXCR1, which was not inhibited by this compound. SB 225002 also demonstrated functional selectivity, since it failed to inhibit calcium mobilization induced by optimal concentrations of LTB 4 in PMNs (Fig. 3C) , or RANTES, MIP-1␣, or MCP-1 in monocytes (data not shown).
Having identified SB 225002 as a potent and selective CXCR2 antagonist, the compound was evaluated for inhibition of human neutrophil chemotaxis in response to maximally effective concentrations of IL-8, GRO␣, or C5a. Using PMNs from nine individual subjects, SB 225002 inhibited both IL-8 (1 nM)-and GRO␣ (10 nM)-mediated chemotaxis with similar IC 50 values (20 and 60 nM, respectively) but did not affect chemotaxis induced by 50 nM C5a at concentrations up to 330 nM (Fig. 4) . These data provide evidence that in vitro neutrophil chemo- 
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taxis is mediated predominantly by CXCR2. Rabbits, like humans, express both IL-8 receptors on their neutrophils (29) . Therefore, this species was utilized to evaluate the in vivo effects of SB 225002. In vitro studies confirmed that SB 225002 is a potent antagonist of rabbit CXCR2, inhibiting rabbit PMN chemotaxis in response to optimal concentrations of human IL-8 or GRO␣ (IC 50 values of 30 and 70 nM, respectively).
In rabbits, an intravenous infusion of LTB 4 , or other chemotactic factors, rapidly promotes neutrophil shape change and margination of neutrophils to the microcapillary endothelial cells of the lung (27, 30 -32) . Thus, this is the basis of a useful model to study the initial stages of neutrophil activation and attachment to the endothelium. As seen in Fig. 5, A and B , administration of IL-8 or fMLP resulted in rapid margination of neutrophils (62 and 68%, respectively), which lasted throughout the infusion period (30 min). Co-administration of SB 225002 (Fig. 5, A and B) inhibited, in a dose-dependent manner, IL-8-, but not fMLP-, mediated PMN sequestration (Fig. 5C) .
The in vitro and in vivo findings presented provide evidence that inhibition of CXCR2 is sufficient to prevent neutrophil margination and chemotaxis mediated by IL-8 and suggests that CXCR1 does not play a major role in neutrophil migration. The functional role of CXCR1 is not clear; however, a recent report, using modified antagonist forms of IL-8 and human neutrophils, demonstrated the importance of CXCR1 in IL-8-mediated superoxide generation and release of granular enzymes (33) . This is consistent with the previous suggestion that CXCR1 on human neutrophils may require higher concentrations of IL-8 for chemotaxis and, therefore, may be involved in neutrophil activities closer to the site of injury and not in the early attachment and extravasation events (10) . This hypothesis agrees with the finding in rodents, which appear to possess only the CXCR2 homologue, yet retain the ability to localize neutrophils to sites of inflammation (17) .
The present study represents the first reported discovery of a potent and selective non-peptide antagonist of a chemokine receptor and the first low molecular weight inhibitor of a large (72 amino acid) agonist 7-TMR interaction. A number of small molecule antagonists have been reported for small peptide receptors, e.g. tachykinin (34), angiotensin (35) , and endothelin (36) , but to our knowledge the only antagonist reported for a large peptide receptor was a micromolar antagonist of the C5a receptor (37) . As chemokine receptors are part of the 7-TMR family, which have traditionally been productive targets for drug discovery, it is anticipated that small molecule receptor antagonists may have potential as novel therapeutics. The availability of potent and selective non-peptide antagonists, such as SB 225002, will help define the apparent overlap in activities of the chemokines and their receptors and elucidate their relative importance. In particular, SB 225002 will be an important tool compound to assess the role of IL-8 and CXCR2 in neutrophil recruitment, a process that is thought to be important in several inflammatory diseases, including adult respiratory distress syndrome, chronic bronchitis, and asthma (38 -41) .
